Prevention of : Herpes-Zoster Clinical Trial
Official title:
An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age
Primary objective:
Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster
virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month
schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at 4 weeks
post-vaccination
Secondary objectives Immunogenicity
- To summarise the VZV antibody titres at 4 weeks post-vaccination after a 1-dose regimen
and 4 weeks post-vaccination after each dose of each 2-doses regimen of ZOSTAVAX®.
- To compare the VZV antibody titres at 12 months after completion of a 1-dose regimen
with the VZV antibody titres at 12 months after completion of each 2-doses regimen of
ZOSTAVAX®
- To summarise the VZV antibody titres at 24 and 36 months after completion of a 1-dose
regimen and at 24 and 36 months after completion of each 2-doses regimen of ZOSTAVAX®
n/a